<DOC>
	<DOCNO>NCT01837927</DOCNO>
	<brief_summary>This study ass Efficacy NVA237 ( 50 μg o.d ) use tiotropium ( 5μg μg o.d ) active control COPD patient .</brief_summary>
	<brief_title>Efficacy NVA237 ( 50 μg o.d ) Using Tiotropium ( 5μg μg o.d ) Active Control COPD Patients .</brief_title>
	<detailed_description>A 52-week treatment , multicenter , randomize , open-label , parallel-group study ass efficacy NVA237 ( 50μg daily ) use Tiotropium ( 5μg daily ) active control Brazilian patient moderate severe Chronic Obstructive Pulmonary Disease .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion : Men woman age 40 year . History current former smoking least 10 packyears Cooperative outpatient , COPD diagnosis establish measurement FEV1/FVC &lt; 0.7 postbronchodilation basal spirometry ( without use medication postwashout ) . Moderate severe stage patient include , postbronchodilator FEV1 30 80 % normal value accord GOLD 2011 since inclusion criterion trial base spirometry result . Exclusion : Pregnant woman nurse mother History asthma visit 1 indicate , limited : Onset respiratory symptom suggestive asthma ( cough , wheeze , shortness breath ) age 40 . History diagnose asthma History respiratory tract infection within six week prior Visit 1 . History hospitalization emergency care COPD exacerbation 3 month prior Visit 1 . Subjects require use home oxygen therapy . Patients active phase assist pulmonary rehabilitation program patient complete rehabilitation program within 18 month Visit 1 2 protocol.17,20 Patients know history diagnosis alpha1 antitrypsin deficiency . Patients concomitant lung disease , e.g . : tuberculosis ( unless confirm radiography inactive ) clinically significant bronchiectasis . Patients investigator 's judgment abnormality significant medical condition : unstable ischemic heart disease , leave ventricular failure , history myocardial infarction , arrhythmia ( except chronic stable atrial fibrillation ) , history malignancy system ( include lung cancer ) treat within last 5 year , glaucoma , prostatic hyperplasia , moderate severe renal impairment , urinary retention , condition might compromise patient safety compliance , interfere evaluation , prevent termination participation study . Patients contraindication tiotropium ipratropium treatment experience undesirable reaction inhale anticholinergic agent patient history undesirable reaction sympathomimetic amine inhale medication component , history hypersensitivity study medication , include rescue medication , similar class medication . Patients use tiotropium , longacting anticholinergic , shortacting anticholinergic , fix combination inhale beta agonist inhale corticosteroid , theophylline . In case , patient allow , agree participate study , enter washout period Visit Patients use inhaled steroid , alone exchange fixed combination equivalent dos , unless stable treatment least 1 month prior randomization Patients use nonselective betablockers . Patients use cromoglycate , nedocromil , ketotifen leukotriene antagonist unless stable treatment least 1 month prior randomization . Patients used oral prednisone ( equivalent ) long period , define ≥ 10 mg/day least 1 month prior Visit 1 Patients use intramuscular depot corticosteroid within 30 day Visit 1 . Patients history long QT Syndrome prolong QTc ( &gt; 450 m ) measure Visit 1 ( Fridericia Method ) . Patients , opinion investigator , clinically significant abnormality ECG . These patient rescreened . Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Efficacy , NVA237 , Tiotropium , Chronic Obstructive Pulmonary Disease , COPD</keyword>
</DOC>